Kondo, M., Ji, L., Kamibayashi, C., Tomizawa, Y., Randle, D., Sekido, Y., Yokota, J., Kashuba, V., Zabarovsky, E., Kuzmin, I., Lerman, M., Roth, J. and Minna, J.D. (2001) Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells. Oncogene, 20, 6258-6262.
 Lerman, M.I., Glenn, G.M., Daniel, L., Latif, F., Hosoe, S., Brauch, H., Hampsch, K., Delisio, J., Orcutt, M. and Zbar, B. (1990) A new polymorphic probe on chromosome 3p: Lambda LIB28-77 (D3S169E). Nucleic Acids Research, 18, 205.
 Lerman, M.I. and Minna, J.D. (2000) The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: Identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Research, 60, 6116-6133.
 Uno, F., Sasaki, J., Nishizaki, M., Carboni, G., Xu, K., Atkinson, E.N., Kondo, M., Minna, J.D., Roth, J.A. and Ji, L. (2004) Myristoylation of the FUS1 protein is required for tumor suppression in human lung cancer cells. Cancer Research, 64, 2969-2976.
 Prudkin, L., Behrens, C., Liu, D.D., Zhou, X., Ozburn, N.C., Bekele, B.N., Minna, J.D., Moran, C., Roth, J.A., Ji, L. and Wistuba, L.L. (2008) Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clinical Cancer Research, 14, 41-47.
 Ito, I., Ji, L., Tanaka, F., Saito, Y., Gopalan, B., Branch, C.D., Xu, K., Atkinson, E.N., Bekele, B.N., Stephens, L.C., Minna, J.D., Roth, J.A. and Ramesh, R. (2004) Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Therapy, 11, 733-739.
 Deng, W.G., Kawashima, H., Wu, G., Jayachandran, G., Xu, K., Minna, J.D., Roth, J.A. and Ji, L. (2007) Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non- small cell lung cancer cells. Cancer Research, 67, 709-717.
 Tsukamoto, H., Fukudome, K., Kohara, J., Nakatake, H. and Kimoto, M. (2007) Preparation of recombinant murine tumor necrosis factor-alpha in Escherichia coli: A rapid method to remove tags from fusion proteins by thrombin-cleavage and ion-exchange chromatography. Protein Expression and Purification, 56, 138-144.
 Zhao, X.Y., Li, H.X., Liang, S.F., Yuan, Z., Yan, F., Ruan, X.Z., You, J., Xiong, S.Q., Tang, M.H. and Wei, Y.Q. (2008) Soluble expression of human DRR1 (down-regulated in renal cell carcinoma 1) in Escherichia coli and preparation of its polyclonal antibodies. Biotechnology and Appied Biochemistry, 49, 17-23.
 Benzinger, A., Muster, N., Koch, H.B., Yates, J.R. and Hermeking, H. (2005) Targeted proteomic analysis of 14-3-3 sigma, a p53 effector commonly silenced in cancer. Molecular & Cellular Proteomics, 4, 785-795.
 Wilkinson, R.J., Elliott, P., Carragher, J.F. and Francis, G. (2004) Expression, purification, and in vitro characterization of recombinant salmon insulin-like growth factor-II. Protein Expression and Purification, 35, 334-343.
 Ji, L., Nishizaki, M., Gao, B., Burbee, D., Kondo, M., Kamibayashi, C., Xu, K., Yen, N., Atkinson, E.N., Fang, B., Lerman, M.I., Roth, J.A. and Minna, J.D. (2002) Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Research, 62, 2715-2720.